Skip to main content

How is Kymriah administered?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on July 3, 2025.

Official Answer by Drugs.com

Kymriah is administered as a suspension through a tube (intravenous catheter) into your vein, typically in your arm. This single-dose infusion usually takes less than one hour.

You might receive your infusion in a healthcare center that may not be close to your home. You will need to stay close to a healthcare center after getting Kymriah, usually for at least 14 days, to receive special treatment if needed, and to monitor for side effects. Avoid driving for at least 2 weeks after receiving Kymriah.

Before you receive Kymriah, you may have chemotherapy for a few days to help prepare your body to receive the treatment.

What did the FDA approve Kymriah for?

ALL, DLBCL and FL are all types of blood cancers that affect blood cells and their production in the bone marrow.

Related questions

How is Kymriah made?

Kymriah is made from your own white blood cells in a process called leukapheresis.

This is not all the information you need to know about Kymriah (tisagenlecleucel) for safe and effective use and does not take the place of your doctor's directions. Review the full product information and discuss this information and any questions you have with your doctor or other health care provider.

References

Read next

What type of drug is Kymriah (tisagenlecleucel)?

Kymriah (tisagenlecleucel) is a chimeric antigen receptor T cell (CAR-T) therapy. In CAR-T cell therapy, a patient's cells are genetically modified to include a new protein that directs that specific white blood cell (known as T-cell) to target and kill leukemia cells.

Continue reading

What is the difference between Truxima and Rituxan?

Truxima (rituximab-abbs) is a biosimilar to Rituxan (rituximab). While both drugs are CD20-directed cytolytic antibodies used to treat non-Hodgkin’s lymphoma (NHL), Rituxan has additional FDA-approved indications beyond NHL. Continue reading

What is the success rate of Rituxan (rituximab) in patients with blood cancers?

In patients with hematological or blood cancers, including non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), Rituxan’s success is measured in a number of ways. It is measured by looking at how long patients responded to treatment (median duration of response), how long they live without their disease progressing (progression-free survival) and how many patients respond to treatment (response rate).

Rituxan treatment improves outcomes in certain patients with NHL. Adding Rituxan alongside standard therapies enhances the response patients have to treatment and improves overall outcomes, including increasing the time patients live for without experiencing a progression of their disease.

Rituxan helps to improve overall survival in certain patients with CLL and also helps to increase the time patients live for without experiencing disease progression. Adding Rituxan alongside standard therapy enhances the response patients have to therapy. Continue reading

See also:

Related medical questions

Drug information

Related support groups